Presbyterian Kaseman Hospital - New Mexico Cancer Research Alliance (NMCRA)
Albuquerque, NM
Accepting patients
VMD-928
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2